Apyx Medical (APYX) Short term Debt (2010 - 2023)

Apyx Medical (APYX) reported Short term Debt of $8.9 million for Q2 2023, up 1.3% quarter-over-quarter from $8.8 million in Q1 2023.

Apyx Medical (APYX) Short term Debt (2010 - 2023) Analysis & Trends

Apyx Medical has reported Short term Debt for 12 years, with the latest figure at $8.9 million in Q2 2023.

For the quarter ending Q2 2023, Short term Debt changed N/A year-over-year to $8.9 million; the trailing twelve-month figure through Jun 2023 stood at $8.9 million (changed N/A YoY), and the FY2019 full-year result was $140000.0, changed N/A from the prior year.
Short term Debt for Q2 2023 stood at $8.9 million, up from $8.8 million in the prior quarter.
The five-year high for Short term Debt was $8.9 million in Q2 2023, with the low at $140000.0 in Q4 2019.
Historically, Short term Debt has averaged $3.0 million across 3 years, with a median of $140000.0 in 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	152.92 Bn	146.27 Bn	6.27 Bn
2	Stryker	119.50 Bn	116.62 Bn	3.81 Bn
3	Medtronic	102.71 Bn	94.54 Bn	5.76 Bn
4	Boston Scientific	69.72 Bn	68.51 Bn	3.61 Bn
5	Edwards Lifesciences	49.24 Bn	45.57 Bn	1.29 Bn
6	GE HealthCare Technologies	29.74 Bn	27.67 Bn	1.98 Bn
7	Koninklijke Philips	29.38 Bn	26.07 Bn	2.07 Bn
8	Dexcom	28.96 Bn	27.84 Bn	750.30 Mn
9	Steris	20.31 Bn	19.88 Bn	697.10 Mn
10	Apyx Medical	205.37 Mn	174.49 Mn	7.93 Mn

Download Data